Skip to content
Catalyst

N-hexadecanoylethanolamineFinding

N-hexadecanoylethanolamine has no detected effect on total nasal symptom score (TNSS)

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“No significant difference was seen between the Levagen+ and placebo groups for the allergy symptoms scores (rTNSS) at baseline or throughout the 14 days of treatment.”
Quoted verbatim from The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.
This finding among the 1 finding on its endpoint

N-hexadecanoylethanolamine

Total nasal symptom score (TNSS)

no difference found

Who
Adults aged 21 to 77 years with seasonal allergic rhinitis, 108 randomised and 101 completed; whole-population comparison, reflective total nasal symptom score recorded online twice daily
Dose studied
Levagen+ (PEA) 350 mg daily, two 175 mg capsules each morning, against placebo of 175 mg maltodextrin per capsule

Moderate evidencePMID 38068797 · 2023

02 · The study

Study
RCT
Duration
14 days

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7ESDTHR0XQ1B34NPGC3F38M